New beginnings for matrix metalloproteinase inhibitors: Identification of high-affinity zinc-binding groups

被引:137
作者
Puerta, DT [1 ]
Lewis, JA [1 ]
Cohen, SM [1 ]
机构
[1] Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA
关键词
D O I
10.1021/ja0485513
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
In an effort to identify promising non-hydroxamate inhibitors of matrix metalloproteinases (MMPs), several new zinc-binding groups (ZBGs) based on pyrone, pyrothione, hydroxypyridinone, and hydroxypyridinethione chelators have been examined. Structural studies with tris(pyrazolyl)borate model complexes show that these ligands bind to the MMP active site zinc(II) ion in a bidentate fashion, similar to that found with hydroxamate-based inhibitors. Fluorescence- and colorimetric-based enzyme assays have been used to determine the IC50 values for these ZBGs against MMP-3; mixed O,S-donor ligands were found to be remarkably potent, with IC50 values as much as 700-fold lower than that found for acetohydroxamic acid. Inhibitory activity was found to parallel metal binding affinity as determined in titrations with model complexes. These results demonstrate that MPIs based on new ZBGs are feasible and may indeed improve the overall performance of inhibitors designed against these important medicinal targets. Copyright © 2004 American Chemical Society.
引用
收藏
页码:8388 / 8389
页数:2
相关论文
共 16 条
[1]   LEAD SEQUESTERING AGENTS .2. SYNTHESIS OF MONO(HYDROXYPYRIDINETHIONE) AND BIS(HYDROXYPYRIDINETHIONE) LIGANDS AND THEIR LEAD COMPLEXES - STRUCTURE OF BIS(6-(DIETHYLCARBAMOYL)-1-HYDROXY-2(1H)-PYRIDINE-2-THIONATO-O,S)LEAD(II) [J].
ABUDARI, K ;
KARPISHIN, TB ;
RAYMOND, KN .
INORGANIC CHEMISTRY, 1993, 32 (14) :3052-3055
[2]   Cancer therapy - Matrix metalloproteinase inhibitors and cancer: Trials and tribulations [J].
Coussens, LM ;
Fingleton, B ;
Matrisian, LM .
SCIENCE, 2002, 295 (5564) :2387-2392
[3]  
Golub L M, 1998, Adv Dent Res, V12, P12
[4]   NMR-based modification of matrix metalloproteinase inhibitors with improved bioavailability [J].
Hajduk, PJ ;
Shuker, SB ;
Nettesheim, DG ;
Craig, R ;
Augeri, DJ ;
Betebenner, D ;
Albert, DH ;
Guo, Y ;
Meadows, RP ;
Xu, LH ;
Michaelides, M ;
Davidsen, SK ;
Fesik, SW .
JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (26) :5628-5639
[5]   Discovery of potent nonpeptide inhibitors of stromelysin using SAR by NMR [J].
Hajduk, PJ ;
Sheppard, G ;
Nettesheim, DG ;
Olejniczak, ET ;
Shuker, SB ;
Meadows, RP ;
Steinman, DH ;
Carrera, GM ;
Marcotte, PA ;
Severin, J ;
Walter, K ;
Smith, H ;
Gubbins, E ;
Simmer, R ;
Holzman, TF ;
Morgan, DW ;
Davidsen, SK ;
Summers, JB ;
Fesik, SW .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1997, 119 (25) :5818-5827
[6]   A NOVEL COUMARIN-LABELED PEPTIDE FOR SENSITIVE CONTINUOUS ASSAYS OF THE MATRIX METALLOPROTEINASES [J].
KNIGHT, CG ;
WILLENBROCK, F ;
MURPHY, G .
FEBS LETTERS, 1992, 296 (03) :263-266
[7]   Metal complexes of the trans-influencing ligand thiomaltol [J].
Lewis, JA ;
Puerta, DT ;
Cohen, SM .
INORGANIC CHEMISTRY, 2003, 42 (23) :7455-7459
[8]   Synthetic analogues relevant to the structure and function of zinc enzymes [J].
Parkin, G .
CHEMICAL REVIEWS, 2004, 104 (02) :699-767
[9]   Elucidating drug-metalloprotein interactions with tris(pyrazolyl)borate model complexes [J].
Puerta, DT ;
Cohen, SM .
INORGANIC CHEMISTRY, 2002, 41 (20) :5075-5082
[10]   Examination of novel zinc-binding groups for use in matrix metalloproteinase inhibitors [J].
Puerta, DT ;
Cohen, SM .
INORGANIC CHEMISTRY, 2003, 42 (11) :3423-3430